Russell Investments Group Ltd. Has $1.04 Million Stock Position in Alector, Inc. (NASDAQ:ALEC)

Russell Investments Group Ltd. grew its stake in shares of Alector, Inc. (NASDAQ:ALEC – Get Rating) by 32.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 112,309 shares of the company’s stock after acquiring an additional 27,594 shares during the period. Russell Investments Group Ltd. owned 0.14% of Alector worth $1,037,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ALEC. Raymond James & Associates bought a new stake in Alector in the 1st quarter valued at $1,106,000. Bank of New York Mellon Corp increased its position in Alector by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 206,696 shares of the company’s stock worth $2,945,000 after acquiring an additional 1,983 shares during the period. American Century Companies Inc. raised its stake in Alector by 84.7% in the 1st quarter. American Century Companies Inc. now owns 140,887 shares of the company’s stock worth $2,008,000 after purchasing an additional 64,589 shares in the last quarter. AlphaCrest Capital Management LLC bought a new stake in Alector in the 1st quarter valued at about $404,000. Finally, MetLife Investment Management LLC grew its position in shares of Alector by 54.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,825 shares of the company’s stock worth $454,000 after purchasing an additional 11,276 shares in the last quarter. Institutional investors and hedge funds own 64.96% of the company’s stock.

Insider Activity at Alector

In other Alector news, insider Gary Romano sold 3,238 shares of Alector stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $8.32, for a total value of $26,940.16. Following the completion of the sale, the insider now directly owns 104,737 shares in the company, valued at $871,411.84. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Gary Romano sold 3,238 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $8.32, for a total transaction of $26,940.16. Following the completion of the sale, the insider now owns 104,737 shares of the company’s stock, valued at approximately $871,411.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 5,849 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.32, for a total transaction of $48,663.68. Following the transaction, the chief executive officer now owns 1,628,546 shares in the company, valued at approximately $13,549,502.72. The disclosure for this sale can be found here. Insiders have sold a total of 25,564 shares of company stock worth $180,802 in the last 90 days. Corporate insiders own 12.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Mizuho cut their price target on shares of Alector from $15.00 to $12.00 in a report on Friday, March 3rd. Morgan Stanley decreased their target price on Alector from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Friday, March 3rd. BTIG Research dropped their target price on shares of Alector from $54.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, March 2nd. Citigroup decreased their price target on shares of Alector from $17.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Finally, Barclays dropped their price objective on shares of Alector from $14.00 to $12.00 in a research note on Friday, May 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.43.

Alector Trading Down 3.5 %

NASDAQ ALEC opened at $7.37 on Friday. The business’s 50-day moving average price is $6.71 and its two-hundred day moving average price is $7.94. The firm has a market capitalization of $614.30 million, a PE ratio of -4.55 and a beta of 0.79. Alector, Inc. has a 12 month low of $5.76 and a 12 month high of $13.50.

Alector (NASDAQ:ALEC – Get Rating) last announced its earnings results on Tuesday, February 28th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.09). The firm had revenue of $14.44 million for the quarter, compared to the consensus estimate of $35.37 million. Alector had a negative return on equity of 57.31% and a negative net margin of 107.05%. As a group, analysts forecast that Alector, Inc. will post -3.06 earnings per share for the current fiscal year.

About Alector

(Get Rating)

Alector, Inc operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.